Skip to Content


In the US, Vinblastine (vinblastine systemic) is a member of the drug class mitotic inhibitors and is used to treat Breast Cancer, Cancer, Choriocarcinoma, Histiocytosis, Hodgkin's Lymphoma, Kaposi's Sarcoma, Lymphoma, Mycosis Fungoides and Testicular Cancer.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Cytostatic agent

Vinca alkaloid

Chemical Name


Foreign Names

Generic Names

  • Vinblastina (OS: DCIT)
  • Vinblastine (OS: BAN, DCF)
  • Vincaleukoblastin (IS)
  • Vinblastine Sulfate (OS: USAN, JAN, BANM)
  • LE-29060 (IS)
  • NSC 49842 (IS)
  • Vincaleukoblastine Sulfate (IS)
  • VLB (IS)
  • Vinblastine (sulfate de) (PH: Ph. Eur. 8)
  • Vinblastine Sulfate (PH: BP 2016, JP XVI, Ph. Int. 4, USP 38)
  • Vinblastine sulfate (PH: Ph. Eur. 8)
  • Vinblastini sulfas (PH: Ph. Eur. 8, Ph. Int. 4)
  • Vinblastinsulfat (PH: Ph. Eur. 8)

Brand Names


BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.